SMARCA4 and cancer: In addition, SMARCA2, which has been added to the gene level, shares a sequence similarity of up to 79.04% with SMARCA4, and Tian et al. [150] claimed that SMARCA2 could be a novel therapeutic target as a key synthetic lethal target in SMARCA4-deficient cancers.